drugset / Trial / NCT01109121

Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

NCT01109121

Phase 2 Completed 112 enrolled Nuon Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This Phase 2 study will be a multicenter, double-blind, randomized, active-comparator study to evaluate the safety and efficacy of tranilast in combination with allopurinol in patients with hyperuricemia and moderate to severe gout.

Timeline

Start
2010-06
Primary completion
2010-12
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 400 mg
Comparator Allopurinol Small molecule 600 mg
Subject Tranilast Small molecule 300 mg

Indications